Please assess the completion status of the following clinical trial:

Trial Title: Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Only patients having signed the consent form regarding study information, data transfer and data use~* The patients suffer from idiopathic Parkinson's Disease (iPD) treated with a combination of L-dopa or another oral iPD drug and Neupro® for at least one month~* The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater)~* The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study~Exclusion Criteria:~* Patients not fulfilling the inclusion criteria~* And according to Summary of Product Characteristics (SmPC): Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neupro® Treatment (Type: None): Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®

Based on this trial design, predict the completion outcome and termination type (if applicable).